These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 10083274)

  • 1. Chimerism-induced remission of overt diabetes in nonobese diabetic mice.
    Li H; Inverardi L; Ricordi C
    Transplant Proc; 1999; 31(1-2):640. PubMed ID: 10083274
    [No Abstract]   [Full Text] [Related]  

  • 2. Nonmyeloablative bone marrow transplantation based on deletion of host-anti-donor alloreactive cells prevents autoimmune insulitis and diabetes in nonobese diabetic mice.
    Elkin G; Prighozina TB; Gurevitch O; Slavin S
    Transplant Proc; 2002 Jun; 34(4):1303-6. PubMed ID: 12072346
    [No Abstract]   [Full Text] [Related]  

  • 3. Mixed bone marrow chimerism as a treatment for autoimmune diabetes.
    Leykin I; Nikolic B; Sykes M
    Transplant Proc; 2001; 33(1-2):120. PubMed ID: 11266737
    [No Abstract]   [Full Text] [Related]  

  • 4. Bone marrow transplantation prevents autoimmune diabetes in nonobese diabetic mice.
    Georgiou HM; Slattery RM; Charlton B
    Transplant Proc; 1993 Oct; 25(5):2896-7. PubMed ID: 8212278
    [No Abstract]   [Full Text] [Related]  

  • 5. Mixed allogeneic chimerism induced by a sublethal approach prevents autoimmune diabetes and reverses insulitis in nonobese diabetic (NOD) mice.
    Li H; Kaufman CL; Boggs SS; Johnson PC; Patrene KD; Ildstad ST
    J Immunol; 1996 Jan; 156(1):380-8. PubMed ID: 8598488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection against autoimmune diabetes in mixed bone marrow chimeras: mechanisms involved.
    Mathieu C; Casteels K; Bouillon R; Waer M
    J Immunol; 1997 Feb; 158(3):1453-7. PubMed ID: 9013991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of diabetes in nonobese diabetic mice by nonmyeloablative allogeneic bone marrow transplantation.
    Elkin G; Prigozhina TB; Slavin S
    Exp Hematol; 2004 Jun; 32(6):579-84. PubMed ID: 15183899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mixed hematopoietic chimerism allows cure of autoimmune diabetes through allogeneic tolerance and reversal of autoimmunity.
    Nikolic B; Takeuchi Y; Leykin I; Fudaba Y; Smith RN; Sykes M
    Diabetes; 2004 Feb; 53(2):376-83. PubMed ID: 14747288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonobese diabetic natural killer cells: a barrier to allogeneic chimerism that can be reduced by rapamycin.
    Al-Adra DP; Chan WF; Anderson CC
    Transplantation; 2011 Nov; 92(9):977-84. PubMed ID: 21956197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inducing tolerance to MHC-matched allogeneic islet grafts in diabetic NOD mice by simultaneous islet and bone marrow transplantation under nonirradiative and nonmyeloablative conditioning therapy.
    Wu T; Levay-Young B; Heuss N; Sozen H; Kirchhof N; Sutherland DE; Hering B; Guo Z
    Transplantation; 2002 Jul; 74(1):22-7. PubMed ID: 12134094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection against autoimmune diabetes by induction of mixed bone marrow chimerism.
    Mathieu C; Vandeputte M; Bouillon R; Waer M
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1266-7. PubMed ID: 8442108
    [No Abstract]   [Full Text] [Related]  

  • 12. Elimination of insulitis and augmentation of islet beta cell regeneration via induction of chimerism in overtly diabetic NOD mice.
    Zhang C; Todorov I; Lin CL; Atkinson M; Kandeel F; Forman S; Zeng D
    Proc Natl Acad Sci U S A; 2007 Feb; 104(7):2337-42. PubMed ID: 17267595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of mixed bone marrow chimerism as potential therapy for autoimmune (type I) diabetes: experience in the NOD model.
    Mathieu C; Bouillon R; Rutgeerts O; Waer M
    Transplant Proc; 1995 Feb; 27(1):640-1. PubMed ID: 7879129
    [No Abstract]   [Full Text] [Related]  

  • 14. Patterns of hemopoietic reconstitution in nonobese diabetic mice: dichotomy of allogeneic resistance versus competitive advantage of disease-resistant marrow.
    Kaufman CL; Li H; Ildstad ST
    J Immunol; 1997 Mar; 158(5):2435-42. PubMed ID: 9036994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low levels of allogeneic but not syngeneic hematopoietic chimerism reverse autoimmune insulitis in prediabetic NOD mice.
    Kaminitz A; Mizrahi K; Yaniv I; Farkas DL; Stein J; Askenasy N
    J Autoimmun; 2009 Sep; 33(2):83-91. PubMed ID: 19632089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A substantial level of donor hematopoietic chimerism is required to protect donor-specific islet grafts in diabetic NOD mice.
    Guo Z; Wu T; Sozen H; Pan Y; Heuss N; Kalscheuer H; Sutherland DE; Blazar BR; Hering BJ
    Transplantation; 2003 Apr; 75(7):909-15. PubMed ID: 12698073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of bone marrow and thymus chimerism between non-obese diabetic (NOD) and NOD-E transgenic mice, on the expression and prevention of diabetes.
    Parish NM; Chandler P; Quartey-Papafio R; Simpson E; Cooke A
    Eur J Immunol; 1993 Oct; 23(10):2667-75. PubMed ID: 8405065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clonal deletion is one mechanism responsible for tolerance in mixed hematopoietic chimeras.
    Orloff SL; Hirose R; Lin Z; Narumi S; Stock PG; Ascher NL
    Transplant Proc; 1997; 29(1-2):1198-200. PubMed ID: 9123270
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of STZ administration on islet isograft and allograft survival in NOD mice.
    Takayama Y; Ichikawa T; Maki T
    Diabetes; 1993 Feb; 42(2):324-9. PubMed ID: 8425668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term abrogation of autoimmune diabetes in nonobese diabetic mice by immunotherapy with anti-lymphocyte serum.
    Maki T; Ichikawa T; Blanco R; Porter J
    Proc Natl Acad Sci U S A; 1992 Apr; 89(8):3434-8. PubMed ID: 1565635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.